http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 Nov 2024 15:28:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/Press+Releases/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/PRNewswire/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/PRNewswire/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA http://www.streetinsider.com/PRNewswire/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..bergen" idsrc="xmltag.org" >BERGEN, Norway</location></span>, <span class="legendSpanClass"><chron>Nov. 20, 2024</chron></span> /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of <person>Olav Hellebø</person> as CEO. <person>Mr. Hellebø</person> will assume the position on <chron>November 21, 2024</chron>.</p> <p><person>Mr. Hellebø</person> brings three decades of experience in the pharmaceutical and biotechnology industries. Since 2023, he has served as board director in the clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has been a board director at the clinical stage biopharmaceutical company, <span>Antev Ltd</span>, specializing in urology and oncology http://www.streetinsider.com/PRNewswire/BerGenBio+Appoints+Olav+Helleb%C3%B8+as+CEO/24011107.html Wed, 20 Nov 2024 15:28:00 -0500 0RU5 7BG 7BG 7BG 7BG 7BG0 7BG0 7BG0 7BG0 A.05841669 A.17530805 A.36526178 BGBIO BGBIO BGBIO.OL BGBIOO BRRGD BRRGF O.00384685 O.00392470 O.01684992 O.07342971 OSAKA